Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

“Partnering with Genesis Therapeutics presents a unique opportunity to leverage their AI technologies to accelerate the ...

Incyte (INCY) and Genesis Therapeutics announced that the companies have entered into a strategic collaboration focused on the research, ...

Incyte and Genesis Therapeutics have agreed to discover and optimize at least two initial small molecule compounds through Genesis’s AI platform, Genesis Exploration of Molecular Space (GEMS).

Incyte and Genesis Therapeutics have entered a strategic partnership aimed at the research, discovery and development of new small-molecule medicines. Incyte will choose the initial collaboration ...

This unique rating measures technical performance by showing how a stock's price action over the last 52 weeks measures up ...

Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of March: ...

Vontobel Holding Ltd. reduced its stake in shares of Incyte Co. (NASDAQ:INCY – Free Report) by 23.7% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 9,467 shares of ...

Incyte has a strong track record of revenue growth and a robust pipeline, targeting over 10 high-impact product launches by ...

Incyte stock was one of the biggest decliners on the S&P 500 Monday after the drugmaker's fourth-quarter adjusted profit and ...

Incyte has broken off its immuno-oncology deal with Agenus. The step, which follows a series of program terminations, will ...

Incyte says 2025 is expected to be a year of defining catalysts with four launches, four pivotal study readouts, at least ...